eligibility_summary
Adults ≥18, ECOG 0–1, measurable disease, adequate organs, UGT1A1 genotyped/tested. Phase I: refractory advanced solid tumors. Phase II: pancreatic, endometrial, gastric/GEJ (HER2-low, CLDN18.2–), RCC, HCC (Child-Pugh A), or other responsive tumors. Biopsy required for Phase II. Key exclusions: Gilbert’s, low UGT1A1/chronic diarrhea, severe GI/respiratory, unstable CNS mets, major CV disease, active autoimmune/infections, recent therapy/surgery, prior CD73/A2AR.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: HB0052, an anti-CD73 antibody–drug conjugate (ADC) given IV every 3 weeks. Drug type and MoA: Monoclonal antibody targeting CD73 (ecto-5′-nucleotidase) conjugated to SN38, the active metabolite of irinotecan and a topoisomerase I inhibitor. Dual mechanism: (1) Blocks CD73’s conversion of AMP to adenosine, reducing adenosine/A2A–A2B receptor–mediated immunosuppression, (2) Delivers SN38 to CD73-expressing cells, causing DNA damage and apoptosis via Topo I inhibition. Cells/pathways targeted: CD73-high tumor cells and CD73+ cells in the tumor microenvironment (e.g., immune and stromal components), adenosinergic pathway (CD73→adenosine→A2A/A2B signaling) and DNA replication/repair (topoisomerase I). Population: patients with advanced solid tumors.